The Mission of NCAI and REACH The NIH Centers for Accelerated Innovations (NCAI) and the NIH Research Evaluation and Commercialization Hubs (REACH) are designed to accelerate translation of scientific discovery into commercial products that improve health for patients. With these two programs, the NIH has created a nationwide network of six Centers and Hubs to develop best practices in translating academic innovations into new drugs, devices, and diagnostics.
How the Programs Work
The NCAI and REACH are unique public-private partnerships with expertise and resources from the federal government, academia, and the private-sector that will change the way discoveries with scientific and commercial potential are identified and developed.
The NCAI joins three Centers in Boston, Ohio, and California, merging the strengths of 14 high-impact research institutions. The REACH program adds three Hubs in New York, Kentucky, and Minnesota to the network. Essential to these programs is upstream consideration of commercial and business issues and industry-style project management with go/no-go milestones. The end result will be de-risked technologies with well-designed business cases primed for licensing or startup company formation.
Support for the Programs
The National Heart, Lung, and Blood Institute started the NCAI in September 2013 and is the primary federal supporter of the program.
REACH is a trans-NIH program implementing the Phase 0 Proof of Concept Partnership pilot program authorized in the 2011 SBIR/STTR Reauthorization Act (P.L. 112-81).